Table 4.
Clinical status |
Compiled numbers (%) |
P-values |
||||
HCC patients with AIH (AIH-series) | HCC patients with PBC (PBC-series) | General-HCC patients | AIH-series/General-HCC patients | PBC-series/General-HCC patients | AIH-series/PBC-series | |
Serum-AFP | Total: 37 | Total: 47 | Total: 15831 | |||
AFP- (< 15 ng/mL) | 15 (40.5) | 13 (27.7) | 5756 (36.4) | P = 0.597 | P = 0.216 | P = 0.214 |
AFP + (>= 15 ng/mL) | 22 (59.5) | 34 (72.3) | 10075 (63.6) | |||
Serum-AFP (ng/mL) | Total: 37 | Total: 47 | Total: 15831 | |||
(mean ± SD) | (2340.21 ± 8823.45) | (854.18 ± 2263.83) | NA | |||
< 15 | 15 (40.5) | 13 (27.6) | 5756 (36.4) | |||
15-199 | 12 (32.5) | 16 (34.0) | 5786 (36.5) | NA | NA | P = 0.106 |
200-399 | 1 (2.7) | 6 (12.8) | 902 (5.7) | (P < 0.001b) | ||
400-999 | 3 (8.1) | 2 (4.3) | 907 (5.7) | |||
>= 1000 | 6 (16.2) | 10 (21.3) | 2480 (15.7) | |||
Maximum tumor size of HCC | Total: 36 | Total: 48 | Total: 15788 | NA | NA | P = 0.744 |
(mean ± SD) (cm) | (3.75 ± 2.42) | (3.51 ± 1.69) | NA | (P = 0.028a) | ||
< 2 | 14 (38.9) | 11 (22.9) | 5123 (32.4) | |||
2.1-5.0 | 16 (44.4) | 29 (60.4) | 7434 (47.1) | |||
>= 5.1 | 6 (16.7) | 8 (16.7) | 3231 (20.5) | |||
Number of HCC loci | Total: 38 | Total: 49 | Total: 16187 | |||
(mean ± SD) | (1.58 ± 2.05) | (1.74 ± 1.97) | NA | NA | NA | P = 0.418 |
Single | 33 (86.8) | 38 (77.6) | 9365 (57.9) | (P = 0.805) | ||
Double | 2 (5.3) | 7 (14.3) | 2850 (17.6) | |||
Multiple | 3 (7.9) | 4 (8.1) | 3972 (24.5) |
The P-value in the first row was calculated from the χ2 test and Fisher’s exact test. The P-value in the following row was calculated from the Mann-Whitney U-test and the P-value below, indicated in parentheses, was calculated from the F-test.
P < 0.05,
P < 0.01, Statistically significant. HCC: Hepatocellular carcinoma; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; AFP: α-fetoprotein; SD: Standard deviation; NA: Not available.